How to Buy Allogene Therapeutics Stock

Allogene Therapeutics Inc

Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

Allogene Therapeutics stock last closed at $5.80, down 0.68% from the previous day, and has decreased 44.55% in one year. It has underperformed other stocks in the Biotechnology industry by 0.3 percentage points. Allogene Therapeutics stock is currently +31.22% from its 52-week low of $4.42, and -66.84% from its 52-week high of $17.49.

There are currently 145.84M shares of ALLO outstanding. The market cap of ALLO is $845.88M. In the last 24 hours, 1.45M ALLO shares were traded.

How to Buy Allogene Therapeutics Stock

Wondering how to invest in Allogene Therapeutics stock? Here's how.
  1. Decide where to buy Allogene Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you determine where to buy Allogene Therapeutics stock.
  2. Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
  3. Fund your brokerage account: Choose your payment method and add your details.
  4. Analyze Allogene Therapeutics stock: The Allogene Therapeutics ticker symbol is ALLO. Is Allogene Therapeutics stock a good investment? Should you buy shares of ALLO? How do ALLO's underlying business fundamentals look? Do top analysts think Allogene Therapeutics is a good buy? Why has ALLO's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if ALLO is a good stock to buy).
  5. Execute your ALLO trade: Decide if you will purchase ALLO shares at the current market price or use a limit order to purchase ALLO stock at a specific price.
  6. Track your investment in ALLO: Create a watchlist to watch your new investment in Allogene Therapeutics stock.

Step 1: Decide where to buy Allogene Therapeutics stock

You need an online brokerage account to access the NASDAQ market and buy ALLO shares.

A brokerage account enables you to buy and sell a variety of investments, including stocks, bonds, mutual funds, and ETFs.

Our preferred brokerage: eToro

In our opinion, eToro is the best brokerage. Here's why:

  • Invest in stocks with 0% commissions: Invest without commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
  • Access to world financial markets: From Tech to Healthcare, New York to London — you can fill your portfolio with stocks from the world's top exchanges.
  • Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
  • Security: eToro is a regulated and licensed fintech leader.
  • Buy other assets: Such as ETFs and cryptocurrencies.

Get $10 towards your share purchase by opening an account with eToro now.

Open eToro Account
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.

Step 2: Sign up for a brokerage account

Now that you've selected your brokerage, you'll need to fill out some personal details so you are able to buy ALLO stock today.

How to Start a New Brokerage Account on eToro

  1. Click here to get started.
  2. Input your personal info to start your new trading account.
  1. Send your details by pressing the "Create Account" button.
Get started with eToro today

Step 3: Fund your brokerage account

Now that you have filled out your info on mobile trading apps, you can securely and quickly fund your account:

Watch this video walkthrough to see the process of depositing money into your new investment account.

Get started with eToro today

Step 4: Analyze Allogene Therapeutics stock

Once you have chosen the best place to buy Allogene Therapeutics stock, it's very important to research their stock prior to buying, so you can wrap your head around the risk and upside.

Allogene Therapeutics Metrics

ALLO Price
1w %
1y %
5y %
Fore. Rev. Growth
Fore. Earn. Growth
Market Cap
Next Earnings
Aug 7, 2023
Next Dividend

ALLO Fundamentals

WallStreetZen was built to help part-time investors perform better fundamental analysis in minutes instead of hours.

You can see all of the due diligence checks on ALLO's stock page.

How is ALLO stock valued?

You can use many financial metrics, analyses, models, and charts to gauge ALLO's intrinsic value.

Using relative valuations metrics:

  • ALLO may be undervalued based on its P/B ratio of 1.43x, relative to Biotechnology industry P/B ratio of 5.24x

You can do additional valuation analysis on ALLO's stock here.

Is ALLO a healthy company?

Passed Health Checks:

  • There are more short-term assets than short-term liabilities on the ALLO balance sheet.
  • ALLO has cash burn of 223245000. It has sufficient cash and short-term investments to cover this for at least one year.
  • ALLO has a low debt to equity ratio of 0.26.
  • ALLO has $481.52M in cash and short term investments. This is sufficient to cover its annual cash burn of $223.25M.
  • There are more short-term assets than long-term liabilities on the ALLO balance sheet.

Failed Health Checks:

  • ALLO profit margin has gone down from -148,214.6% to -150,207.7% in the past year.

Is Allogene Therapeutics stock a Buy, Hold, or Sell, according to analysts?

Out of 12 sell side analysts who monitor ALLO, the consensus analyst rating on ALLO is a Buy

Please note that analyst ratings are not stock recommendations, nor are they financial advice.

Latest ALLO Analyst Recommendations

Reni Benjamin, a top 17% analyst from JMP Securities reiterates ALLO with a buy rating and maintains their ALLO price target from $15.00 to $15.00, on Jun 5, 2023.

Tony Butler, a bottom 5% analyst from EF Hutton reiterates ALLO with a strong buy rating and maintains their ALLO price target from $15.00 to $15.00, on Jun 5, 2023.

Robert Burns, a bottom 1% analyst from HC Wainwright & Co. reiterates ALLO with a buy rating and maintains their ALLO price target from $23.00 to $23.00, on May 5, 2023.

Benjamin Burnett, a bottom 7% analyst from Stifel Nicolaus maintains ALLO with a hold rating and lowers their ALLO price target from $8.00 to $7.50, on May 4, 2023.

Luca Issi, a bottom 8% analyst from RBC Capital reiterates ALLO with a buy rating and maintains their ALLO price target from $15.00 to $15.00, on May 4, 2023.

You can dive deeper into what analysts are forecasting on the Allogene Therapeutics stock forecast page.

ALLO Technicals

MACD Signal
MACD Histogram
Stochastic %K
Stochastic %D
StochRSI %K
StochRSI %D

Is ALLO Growing Revenue?

Last year, ALLO revenue was $234.00k. In the last 2 year, ALLO's revenue has grown by -92.19% per year. This was slower than the Biotechnology industry average of 91.4%.

Find out more about ALLO's earnings and revenue performance here.

Are ALLO insiders buying or selling the stock?

In the past 12 months, executives and large shareholders at ALLO have sold more shares than they have bought.

Veer Bhavnagri, General Counsel of ALLO, was the latest ALLO insider to sell. They sold $133,970.76 worth of ALLO shares on Mar 14, 2023.

Learn more about who owns ALLO stock here.

Can I rely on ALLO as an income stream?

No, Allogene Therapeutics doesn't provide an income stream by paying out dividends.

ALLO Social Trading Data

One of the reasons eToro is our top-rated brokerage is because of its social trading community.

Click below to learn what other investors have to say.

Step 5: Execute your ALLO trade

There are two main order types:

  • Market order: A market order is an order to buy or sell a stock at the best possible price.
    Market orders are generally the best for newer investors.
  • Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
    If you want to ensure you're buying or selling at a particular price limit, use a limit order.

Click the Open button and eToro will execute the order.

If you want additional help buying stocks on eToro, click the helpful video below:

Open eToro Account

Step 6: Track your investment in ALLO

Now that you own some ALLO stock, you'll want to keep up with your stock purchase.

Make a watchlist to track the latest developments regarding your ALLO stock.


How to Buy Stock in Allogene Therapeutics

To reiterate, here are the 6 steps to buy Allogene Therapeutics stock:

  1. Decide where to buy Allogene Therapeutics stock
  2. Sign up for a brokerage account
  3. Fund your brokerage account
  4. Analyze Allogene Therapeutics stock
  5. Execute your ALLO trade
  6. Track your investment in ALLO

If you are looking for a place to buy stocks, eToro is our recommended option.

Get Started with eToro Today

If you would like to watch your investment in Allogene Therapeutics, add ALLO to your watchlist below.

$5.80-0.04 (-0.68%)
Updated Jun 8, 2023
Open eToro Account
$5.80-0.04 (-0.68%)
Updated Jun 8, 2023
Open eToro Account


How much does it cost to buy one Allogene Therapeutics share?

As of Jun 8, 2023, it costs $5.80 to buy one share of Allogene Therapeutics stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $2, you can buy 0.345 shares of ALLO.

Get Started with eToro Today

Is now a good time to buy Allogene Therapeutics stock?

According to 12 Wall Street analysts who monitor Allogene Therapeutics, their consensus recommendation is to buy Allogene Therapeutics stock.

What is the best way to buy Allogene Therapeutics stock?

One way to place an order for Allogene Therapeutics stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.